Explore more publications!
Harrisburg Wellness Reporter
Got News to Share?

Harrisburg Wellness Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 5, 2025

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
December 5, 2025

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Indeterminate GlobeNewswire
Curaechoice and Northwestern Memorial Healthcare Extend Partnership to Expand Access to No-Cost Healthcare for Curaechoice Members Nationwide
December 5, 2025

Curaechoice and Northwestern Memorial Healthcare Extend Partnership to Expand Access to No-Cost Healthcare for Curaechoice Members Nationwide

Indeterminate GlobeNewswire
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 5, 2025

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Indeterminate GlobeNewswire
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
December 5, 2025

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 5, 2025

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Indeterminate GlobeNewswire
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 5, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Indeterminate GlobeNewswire
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 5, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Indeterminate GlobeNewswire
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
December 5, 2025

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Indeterminate GlobeNewswire
GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models
December 5, 2025

GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models

Indeterminate GlobeNewswire
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
December 5, 2025

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

Indeterminate GlobeNewswire
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 5, 2025

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

Indeterminate GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
December 5, 2025

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Indeterminate GlobeNewswire
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
December 5, 2025

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

Indeterminate GlobeNewswire
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
December 5, 2025

ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting

Indeterminate GlobeNewswire
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
December 5, 2025

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Indeterminate GlobeNewswire
Protara Announces Pricing of $75 Million Public Offering
December 5, 2025

Protara Announces Pricing of $75 Million Public Offering

Indeterminate GlobeNewswire
Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine
December 5, 2025

Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

Indeterminate GlobeNewswire
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
December 5, 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Indeterminate GlobeNewswire
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
December 5, 2025

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions